Pancragen vs Retatrutide
Moderate Research vs Extensively Studied
monitor Mechanism-based · 47% Both Pancragen and Retatrutide affect insulin sensitivity or blood glucose. Monitor fasting glucose and HbA1c. Consider adding an insulin sensitizer (metformin/berberine).
Molecular Data
Pancragen Retatrutide
Weight 576 Da 4,731.33 Da
Half-life Not established ~6 days
Chain 4 amino acids 39 amino acids
Type Tetrapeptide bioregulator Triple GLP-1/GIP/glucagon agonist
Key Benefits
Pancragen
01 Corrects impaired glucose tolerance
02 Normalizes insulin levels
03 Normalizes C-peptide levels
04 Improves endocrine pancreatic function
05 Supports pancreatic cell differentiation
06 Regulates melatonin expression
07 Reduces metabolic syndrome incidence
08 Upregulates key pancreatic transcription factors
Retatrutide
01 Superior weight loss (24.2% at 48 weeks)
02 Improved glycemic control (HbA1c reduction up to 2.16%)
03 Enhanced cardiovascular benefits
04 Hepatic fat reduction (up to 82%)
05 Triple mechanism addresses obesity through multiple pathways
Dosing Protocols
Pancragen
10-20mg daily / Daily for 10-20 days per cycle
Research protocol 0.05 mg/kg Daily for 10 days
Retatrutide
0.5mg starting, titrate up to 8-12mg weekly / Once weekly (same day each week)
Starting Dose (Week 1-4) 0.5mg Once weekly
Low Maintenance (Week 4-8) 1mg Once weekly
Escalation (Week 8-12) 2mg Once weekly
Moderate (Week 12-16) 4mg Once weekly
Advanced (Week 16-20) 8mg Once weekly
Maximum Efficacy (Week 20+) 12mg Once weekly
Side Effects
Pancragen
Generally well-tolerated
Minimal side effects reported
Retatrutide
Gastrointestinal effects (nausea, vomiting, diarrhea)—typically mild to moderate
Heart rate increases—common especially in first 24 weeks
Appetite suppression
Mild dehydration
Contraindications
Active pancreatic emergencies (seek medical care)
Known hypersensitivity
Pregnancy or breastfeeding
Type 1 diabetes (consult physician)
Personal or family history of medullary thyroid carcinoma
MEN2 syndrome
Severe renal impairment
Research Evidence
Pancragen Retatrutide
Status Moderate Research Extensively Studied
References 4 studies 6 studies
Latest — 2025-10
FDA Approved No No
This comparison is for educational and research purposes only. Consult a healthcare professional before use.